Gilead Sciences (GILD) Tops Q3 EPS by 16c, Remdesivir Revenue $873M in Qtr; Lowers FY EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Gilead Sciences Announces Third Quarter 2020 Financial Results
October 28, 2020 4:01 PM EDTThird Quarter 2020 Highlights: Year-Over-Year
- Product Sales increased 18% to $6.5 billion -
- Product Sales excluding Veklury increased 2% to $5.6 billion -
-Â GAAP Diluted EPS of $0.29 -
-Â Non-GAAP Diluted EPS increased 29% to $2.11 -
-Â Acquisition of Immunomedics, Inc. -
Updated Full Year 2020 Guidance
-Â Product Sales of $23 billion to $23.5 billion -
-... More
